A Medical Research and Evaluation Facility (MREF) and Studies Supporting the Medical Chemical Defense Program on Task 89-03: Test Up to 20 Candidate Topical Protectants
Final rept. Oct 1989-Feb 1992
BATTELLE MEMORIAL INST COLUMBUS OH
Pagination or Media Count:
Fourteen candidate topical skin protectants TSPs were examined in a multiple-phase testing regimen that included a variety of testing models designed to assess different aspects of TSP efficacy. Phase I initial efficacy tests were performed using both in vitro and in vivo models. The Phase I in vitro model involved determining the penetration profile of a challenge dose of chemical surety materiel CSM, either soman GD, VX, or thickened soman TGD, through a 0.1 mm thick film of TSP layered between two disks of synthetic membrane. The in vivo models were performed in New Zealand White rabbits pretreated with 0.1 mm thick layers of TSP. Following topical application of an organophosphonate challenge TGD on rabbits, the end point for determining TSP efficacy was erythrocyte acetylcholinesterase inhibition profiles. Following topical application of a vesicant challenge HD, the end point for TSP efficacy was the size of the lesion resulting after prescribed exposure periods.
- Chemical, Biological and Radiological Warfare